ABSTRACT
The “bench-to-bedside” transfer of placental tissues and cells is a place where research has quite a cozy spot compared to regular production. Placental tissues and cells, however, are harvested at an obstetrical department that itself hardly has any clinical case to use these tissues. The highest costs in the production of placental tissues and cells derived thereof are, for example, related to product loss. Placental tissues and cells encourage integration by scientific work, which should be seen as an opportunity for all persons involved. Legal requirements for tissues are specific regulations that are in accordance to pharmaceutical laws. The production of placental cells and tissues includes a predonation phase that is clearly designed for the prevention of transmissible agents, avoidance of product contamination, and proper donor selection. Producing cells and tissues in a tissue bank or a good manufacturing practice facility requires skill and experience in steady-state procedures with a high level of robust.
